Yamauchi T, Okada K, Yoshida O
Hinyokika Kiyo. 1986 Dec;32(12):1781-97.
We examined the chemotherapies with cis-diamminedichloroplatinum (II) (CDDP) alone and in combination, using the human bladder cancer xenografts (BT-8 and BT-11 strains) in athymic nude mice (BALB/C), to establish the most effective and useful method for urothelial cancer in clinical use. First, to assess the anti-tumor activities of single-drug and our devised VPM or CisCF combination chemotherapies, experiments were done using the BT-8 strain bladder cancer (transitional cell carcinoma and grade III). The schedule and dosage of each chemotherapy were as follows. Vincristine (VCR): 0.06 mg/kg, days 1-6, peplomycin (PEP): 0.9 mg/kg, days 1-6, methotrexate (MTX): 0.6 mg/kg, days 1-6, cytosine arabinoside (Ara-C): 3 mg/kg, days 1-6, 5-fluorouracil (5-FU): 30 mg/kg, days 1-6, adriamycin (ADM): 3 mg/kg, days 1-6, cyclophosphamide (CPM): 10 mg/kg, days 1-10, and CDDP: 2.5 mg/kg, days 1-6. These were for single-drug chemotherapies. The VPM combination consisted of VCR (0.06 mg/kg, days 1 and 4), PEP (0.3 mg/kg, days 1-6) and MTX (0.3 mg/kg, days 2, 3, 5 and 6), and the CisCF combination consisted of CDDP (2.5 mg/kg, days 1 and 4), Ara-C (3 mg/kg, days 1 and 4) and 5-FU (15 mg/kg, days 2, 3, 5 and 6). The control group was given normal saline of 0.1 ml/20 g body weight, intraperitoneally. All anti-cancer drugs were also given intraperitoneally. Secondly, to assess the anti-tumor activities of CDDP alone and various modes of combination chemotherapies with or without CDDP, the following experiments were done using the BT-11 strain bladder cancer (a mixed type of transitional cell carcinoma and squamous cell carcinoma). CDDP: 2.5 mg/kg, days 1-6. VPM X 2: VCR (0.04 mg/kg, days 1, 4, 8 and 11), PEP (0.2 mg/kg, days 1-4) and MTX (0.2 mg/kg, days 2, 3, 5, 6, 9, 10, 12 and 13). CisCF X 2: CDDP (2.5 mg/kg, days 1 and 8), Ara-C (3 mg/kg, days 1, 6, 8 and 13) and 5-FU (30 mg/kg, days 3, 4, 5, 10, 11 and 12). VPM-CisCF (I): VCR (0.04 mg/kg, days 1 and 4), PEP (0.2 mg/kg, days 1-7), MTX (0.2 mg/kg, days 2, 3, 5 and 6), CDDP (2.5 mg/kg, day 8), Ara-C (3 mg/kg, days 8 and 13), and 5-FU (30 mg/kg, days 10-12).(ABSTRACT TRUNCATED AT 400 WORDS)
我们使用无胸腺裸鼠(BALB/C)体内的人膀胱癌异种移植瘤(BT - 8和BT - 11株),研究了顺二氯二氨铂(II)(CDDP)单独及联合化疗,以建立临床上治疗尿路上皮癌最有效且实用的方法。首先,为评估单药及我们设计的VPM或CisCF联合化疗的抗肿瘤活性,使用BT - 8株膀胱癌(移行细胞癌,III级)进行实验。每种化疗的方案和剂量如下。长春新碱(VCR):0.06 mg/kg,第1 - 6天;培普利霉素(PEP):0.9 mg/kg,第1 - 6天;甲氨蝶呤(MTX):0.6 mg/kg,第1 - 6天;阿糖胞苷(Ara - C):3 mg/kg,第1 - 6天;5 - 氟尿嘧啶(5 - FU):30 mg/kg,第1 - 6天;阿霉素(ADM):3 mg/kg,第1 - 6天;环磷酰胺(CPM):10 mg/kg,第1 - 10天;CDDP:2.5 mg/kg,第1 - 6天。这些是单药化疗方案。VPM联合方案由VCR(0.06 mg/kg,第1天和第4天)、PEP(0.3 mg/kg,第1 - 6天)和MTX(0.3 mg/kg,第2、3、5和6天)组成,CisCF联合方案由CDDP(2.5 mg/kg,第1天和第4天)、Ara - C(3 mg/kg,第1天和第4天)和5 - FU(15 mg/kg,第2、3、5和6天)组成。对照组腹腔注射0.1 ml/20 g体重的生理盐水。所有抗癌药物均腹腔给药。其次,为评估CDDP单独及含或不含CDDP的各种联合化疗模式的抗肿瘤活性,使用BT - 11株膀胱癌(移行细胞癌和鳞状细胞癌混合型)进行了以下实验。CDDP:2.5 mg/kg,第1 - 6天。VPM X 2:VCR(0.04 mg/kg,第1、4、8和11天)、PEP(0.2 mg/kg,第1 - 4天)和MTX(0.2 mg/kg,第2、3、5、6、9、10、12和13天)。CisCF X 2:CDDP(